Search research articles
Contact Us
Filters
Showing results (41-50 of 52) with videos related to
Page
of 6
Sort By:
Cancer Immunology, Immunotherapy : CII
|
May 7, 2024
Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data
Justin C Moser, Shailender Bhatia, Asim Amin, et al.
Journal for Immunotherapy of Cancer
|
April 23, 2015
Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
Asim Amin, Arkadiusz Z Dudek, Theodore F Logan, et al.
Cancer
|
July 4, 2025
Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800)
Alexander M Menzies, Pamela Salman, Osvaldo Arén Frontera, et al.
The Lancet. Oncology
|
April 12, 2024
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial
Ana Oaknin, Kathleen Moore, Tim Meyer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 21, 2019
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort
Neal E Ready, Patrick A Ott, Matthew D Hellmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 25, 2025
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naive Advanced Melanoma
Antoni Ribas, Mohammed M Milhem, Christopher J Hoimes, et al.
Cancer Immunology, Immunotherapy : CII
|
October 8, 2016
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
Ajjai Alva, Gregory A Daniels, Michael K K Wong, et al.
The Lancet. Oncology
|
June 9, 2016
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J Antonia, José A López-Martin, Johanna Bendell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 24, 2020
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial
Suzanne L Topalian, Shailender Bhatia, Asim Amin, et al.
Journal for Immunotherapy of Cancer
|
July 15, 2020
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
Robert J Motzer, Bernard Escudier, David F McDermott, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 52) with videos related to
Sort By:
Page
of 6
Cancer Immunology, Immunotherapy : CII
|
May 7, 2024
Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data
Justin C Moser, Shailender Bhatia, Asim Amin, et al.
Journal for Immunotherapy of Cancer
|
April 23, 2015
Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
Asim Amin, Arkadiusz Z Dudek, Theodore F Logan, et al.
Cancer
|
July 4, 2025
Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800)
Alexander M Menzies, Pamela Salman, Osvaldo Arén Frontera, et al.
The Lancet. Oncology
|
April 12, 2024
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial
Ana Oaknin, Kathleen Moore, Tim Meyer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 21, 2019
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort
Neal E Ready, Patrick A Ott, Matthew D Hellmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 25, 2025
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naive Advanced Melanoma
Antoni Ribas, Mohammed M Milhem, Christopher J Hoimes, et al.
Cancer Immunology, Immunotherapy : CII
|
October 8, 2016
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
Ajjai Alva, Gregory A Daniels, Michael K K Wong, et al.
The Lancet. Oncology
|
June 9, 2016
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J Antonia, José A López-Martin, Johanna Bendell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 24, 2020
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial
Suzanne L Topalian, Shailender Bhatia, Asim Amin, et al.
Journal for Immunotherapy of Cancer
|
July 15, 2020
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
Robert J Motzer, Bernard Escudier, David F McDermott, et al.
Page
of 6